PRESS RELEASE PHILADELPHIA, July 30, 2024 A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported today at the Alzheimers Association International Conference (AAIC ) 2024, in Philadelphia and online
Christine Smith-Reed, a salon owner from Columbia City, had tried it all in a bid to lose weight but was never successful in keeping the pounds off
The connection between supplemental carnitine, TMAO, and cardiovascular outcomes requires more targeted human clinical studies
-arrestin recruitment assay PathHunter CHO-GLP-1R -arrestin-1 and -2 reporter cell lines were used, following the manufacturers instructions
Basic hydration treatments are generally on the lower end of the cost spectrum, while more specialized therapies, such as those containing vitamins, antioxidants, and other beneficial compounds, may cost more